PAI-1-resistant t-PA: Low doses prevent fibrin deposition in rabbits with increased PAI-1 activity

Blood

Volumn 87, Issue 1, 1996, Pages 14-19

  Krishnamurti, Chitra ^a   Keyt, Bruce ^b   Maglasang, Peter ^b   Alving, Barbara M ^b  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ENDOTOXIN; FIBRIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT PLASMINOGEN ACTIVATOR; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FIBRIN DEPOSITION; FIBRINOLYTIC THERAPY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBOSIS;

EID: 0030034993     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.1.14.bloodjournal87114     Document Type: Article

References (22)

1. Erickson LA, Hekman CM, Loskutoff DJ: The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related. Proc Natl Acad Sci USA 82:8710, 1985
2. Krishnamurti C, Alving BM: Plasminogen activator inhibitor type 1: Biochemistry and evidence for modulation of fibrinolysis in vivo. Semin Thromb Haemost 18:67, 1992
3. Colucci M, Paramo JA, Collen D: Generation in plasma of a fast acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 75:818, 1985
4. Kruithof EKO, Nicolosa G, Bachmann F: Plasminogen activator inhibitor 1: Development of a radioimmunoassay and observation on its plasma concentration during venous occlusion and after platelet aggregation. Blood 70:645, 1987
5. Stringer HAR, van Swieten P, Heijnen HFG, Sixma JJ, Pannekoek H: Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop. Arterioscler Thromb 14:1452, 1994
6. Fay WP, Eitzman DT, Shapiro AD, Madison EL, Ginsburg D: Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and-independent mechanisms. Blood 83:351, 1994
7. Madison EL, Goldsmith EJ, Gerard RD, Gething M-JH, Sambrook JF: Serpin-resistant mutants of human tissue-type plasminogen activator. Nature 339:721, 1989
8. Madison EL, Goldsmith EJ, Gerard RD, Gething M-JH, Sambrook JF, Bassel-Duby RS: Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1. Proc Natl Acad Sci USA 87:3530, 1990
9. Bennett WF, Paoni NF, Keyt BA, Botstein D, Jones AJS, Presta L, Wurm FM, Zoller MJ: High resolution analysis of functional determinants on human tissue-type plasminogen activator. J Biol Chem 266:5191, 1991
10. Refino CJ, Paoni NF, Keyt BA, Pater CS, Badillo JM, Wurm FM, Ogez J, Bennett WF: A variant of t-PA (T103N, KHRR 296-299 AAAA) that, by bolus, has increased potency and decreased systemic activation of plasminogen. Thromb Haemost 70:313, 1993
11. Krishnamurti C, Bolan C, Colleton CA, Reilly TM, Alving BM: Role of plasminogen activator inhibitor-1 in promoting fibrin deposition in rabbits infused with ancrod or thrombin. Blood 82:3631, 1993
12. Wiman B, Melbring G, Ranby M: Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clin Chim Acta 127:279, 1983
13. Krishnamurti C, Barr CF, Hassett MA, Young DG, Alving BM: Plasminogen activator inhibitor. A regulator of ancrod-induced fibrin deposition in rabbits. Blood 69:798, 1987
14. Chmielewska J, Ranby M, Wiman B: Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 31:427, 1983
15. Bland M: An Introduction to Medical Statistics. Oxford, UK, Oxford University Press, 1987, p 251
16. Krishnamurti C, Young GD, Barr CF, Colleton CA, Alving BM: Enhancement of tissue plasminogen activator-induced fibrinolysis by activated protein C in endotoxin-treated rabbits. J Lab Clin Med 118.523, 1991
17. Carr ME, Krishnamurti C, Alving BM: Effect of plasminogen activator inhibitor-1 on tissue-type plasminogen activator induced fibrinolysis. Thromb Haemost 67:106, 1992
18. Li X-K, Lijnen HR, Nelles L, Van Hoef B, Stassen JM, Collen D: Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1. Blood 79:417, 1992
19. Shohet RV, Spitzer S, Madison EL, Bassel-Duby R, Gething M-J, Sambrook JF: Inhibitor-resistant tissue-type plasminogen activator: An improved thrombolytic agent in vitro. Thromb Haemost 71:124, 1994
20. Paoni NF, Keyt BA, Refino CJ, Chow AM, Nguyen HV, Berleau LT, Badillo J, Pena LC, Brady K, Wurm FM, Ogez J, Bennett WF: A slow clearing, fibrin-specific, PAI-1 resistant variant of t-PA (T103N, KHRR 296-299 AAAA). Thromb Haemost 70:307, 1993
21. Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, Lai J, Pena L, Pater C, Ogez J, Etcheverry T, Botstein D, Bennett WF: A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 91:3670, 1994
22. Collen D, Stassen J-M, Yasuda T, Refino C, Paoni N, Keyt B, Roskams T, Guerrero JL, Lijnen HR, Gold HK, Bennett WF: Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost 72:98, 1994